A sweeping biomedical bill that would help drug and medical device companies win swifter government approval of their products, boost disease ...
News
- What the 114th Congress did and didn't do
- Seattle Genetics Highlights Phase 1 Data for Novel Antibody-Drug Conjugate SGN-LIV1A in ...
SAN ANTONIO--(BUSINESS WIRE)--Seattle Genetics, Inc. (NASDAQ: SGEN), a global biotechnology company, today presented data from an ongoing ...
- Calithera Biosciences to Host Conference Call and Webcast to Review Data Presented at the San ...
... clinical data presentations at the San Antonio Breast Cancer Symposium, ... Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company ...
- KU professor's research proves some science textbooks wrong
Haufler's research is reported in the November issue of the journal Bioscience, in an article he co-authored with a group he said one reviewer ...
- Study: IBM Watson agrees with cancer docs on treatment options 90% of the time
At the San Antonio Breast Cancer Symposium, Dr. S. P. Somashekhar, chairman of the Manipal Comprehensive Cancer Center in Bengaluru, India, ...